KaNDy Therapeutics Successfully Raises £25 Million in a Series C Financing
KaNDy Therapeutics, a clinical-stage Women’s Health company, today announces it has successfully closed a Series C financing round, raising £25 million from new US investor Longitude Capital, and existing internationally recognised life sciences investors Advent Life Sciences, Fountain Healthcare Partners, Forbion Capital Partners and OrbiMed.
The proceeds will enable KaNDy Therapeutics to advance its breakthrough non-hormonal drug candidate, NT-814, for treatment of multiple symptoms of the menopause, through a multi-country Phase 2b dose-ranging study due to start recruiting patients in Q4 2018 with headline results expected in late 2019.
Commenting on the financing round, Mary Kerr CEO of KaNDy Therapeutics, said: "We are delighted by the level of enthusiasm and financial support we have received from our investors and would like to welcome Longitude Capital into the syndicate and the board of directors. Our investors and the KaNDy management team are united by the common belief that NT-814 has the potential to be a transformational treatment for the millions of women worldwide who suffer debilitating symptoms of the menopause.”
NT-814 is an orally administered once daily, potent and selective small molecule dual antagonist of both the neurokinin-1 and 3 receptors. It is being developed by KaNDy Therapeutics to provide a viable alternative to hormone replacement therapy. In June 2018, the Company announced positive data from the Phase Ib/IIa proof of concept clinical trial which showed that women who were treated with NT-814 once daily for two weeks at the most effective doses evaluated, experienced a rapid and profound reduction in two key symptoms of the menopause, namely frequency and severity of hot flashes and the number of night time awakenings
Josh Richardson, M.D., Managing Director of Longitude Capital said: “We were very pleased to participate in this funding round. We have been impressed with the data announced thus far, by KaNDy’s business strategy and the strong and experienced management team. We believe NT-814 has the potential to greatly improve the quality of life of millions of women worldwide and we look forward to supporting the Company as it continues to progress this potentially transformational candidate through the clinic towards commercialization.”
A Phase 2b study to further evaluate the safety and efficacy of NT-814 in women with bothersome post-menopausal symptoms, and to establish the optimum dose to take forward into Phase 3, is anticipated to start recruiting patients in the US, Canada and the UK in Q4 2018, with headline results expected in late 2019.
About KaNDy Therapeutics
KaNDy Therapeutics is a
clinical-stage company focused on optimizing the potential of NT-814 as
a non-hormonal treatment for common, chronic debilitating female
sex-hormone related conditions. These conditions, such as
post-menopausal hot flashes, can impact womens’ quality of life for 10
years or more and are associated with significant social, healthcare and
economic costs.
NT-814 is a once-a-day oral, potent and selective small molecule dual antagonist of both the neurokinin-1 and 3 receptors under development by KaNDy as a therapy for a range of Women’s Health conditions. NT-814 addresses hot flashes by modulating a group of oestrogen sensitive neurones in the hypothalamus in the brain (the KNDy neurones), that in menopausal women due to the absence of oestrogen, become hyperactive and consequently disrupt body heat control mechanisms resulting in the debilitating vasomotor symptoms of HF.
About Advent Life Sciences
Advent Life Sciences is one of
Europe’s leading venture teams investing in life sciences businesses.
The team consists of professionals with extensive scientific, medical
and operational experience, and a long-standing track record of
entrepreneurial and investment success across the UK, Europe and the US.
The firm invests in a range of sectors within life sciences, principally
in new drug discovery, enabling technologies and med tech. Realizations
include Algeta, Avila, CardiAQ, CN Creative, EUSA and Micromet. Current
investments include Acutus, Arrakis, Aura, Axonics, GMPO and NeRRe. For
more information, please visit www.adventls.com.
About Forbion Capital Partners
Forbion is a dedicated life
sciences venture capital firm with offices in The Netherlands and
Germany. Forbion invests in life sciences companies that are active in
the pharmaceutical, as well as the medical device space. Forbion’s
investment team has built an impressive performance track record since
the late nineties with successful investments in over 50 companies.
Forbion manages well over EUR 1 billion across ten funds. Its investors
include the EIF, through its European Recovery Programme (ERP), LfA and
Dutch Venture Initiative (DVI) facilities and the KFW through the ERP –
Venture Capital Fondsfinanzierung facility. Forbion also operates a
joint venture with BGV, the manager of seed and early stage funds
focused on Benelux and Germany. www.forbion.com
About Fountain Healthcare Partners
Fountain Healthcare
Partners is a life science focused venture capital fund with €176
million ($200 million) under management. Within the life science sector,
specific areas of interest to Fountain include specialty pharma, medical
devices, biotechnology and diagnostics. The firm deploys the majority of
its capital in Europe, with the balance in the United States. Fountain’s
main office is in Dublin, Ireland, with a second office in New York. For
more information, please visit www.fh-partners.com.
About Longitude Capital
Longitude Capital is a private
investment firm that makes venture growth investments in biotechnology
and medical technology companies that seek to improve clinical outcomes,
enhance quality of life and/or reduce system costs. Longitude Capital
invests in both privately held and publicly traded life science
companies through a variety of investment approaches. Since 2006,
Longitude Capital has raised over $1.2 billion across three funds and
has offices in Menlo Park, CA and Greenwich, CT. For more information,
please visit www.longitudecapital.com.
About OrbiMed
OrbiMed is a leading healthcare
investment firm, with $14 billion in assets under management. OrbiMed
invests globally across the healthcare industry, from start-ups to large
multinational corporations, utilizing a range of private equity funds,
public equity funds, and royalty/credit funds. OrbiMed maintains offices
in New York City, San Francisco, Shanghai, Hong Kong, Mumbai and
Herzliya. OrbiMed seeks to be a capital provider of choice, providing
tailored financing solutions and global team resources and support to
help build world-class healthcare companies.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180828005866/en/
Contact information
KaNDy Therapeutics
Mary Kerr, Managing Director of KaNDy
Therapeutics
Tel: +44 1438 906960
Email: info@kandytherapeutics.com
or
Consilium
Strategic Communications
Mary-Jane Elliott/ Lindsey Neville/
Carina Jurs
Tel: +44 (0) 20 3709 5700
KaNDyTherapeutics@consilium-comms.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Azafaros Secures € 132M in Oversubscribed Series B Financing to Advance Phase 3 Clinical Programs of Innovative Therapies in Lysosomal Storage Disorders13.5.2025 08:00:00 EEST | Press release
Azafaros, a clinical-stage company focused on developing disease-modifying therapeutics to offer new treatment options to patients with rare lysosomal storage disorders, announces the completion of an oversubscribed €132M Series B financing led by Jeito Capital, co-led by Forbion Growth and with additional participation from Seroba, Pictet Group and existing investors Forbion Ventures, Schroders Capital and BioGeneration Ventures (BGV). This financing enables Azafaros to accelerate the development of its lead product nizubaglustat, scheduled to enter Phase 3 studies for Niemann-Pick disease Type C (NPC) and GM1/GM2 gangliosidoses later this year, as well as expanding the Azafaros pipeline to other indications. Rachel Mears, Partner at Jeito Capital; Julien Elric, Senior Principal at Jeito Capital; and Audrey Cacaly, Principal at Forbion Growth will also join Azafaros’s Board of Directors as Board members. Founded in 2018 by BGV, leveraging science from Leiden University and Amsterdam U
Presidio Investors is Pleased to Announce the Addition of Christian Schütte as Its Newest Operating Partner12.5.2025 20:04:00 EEST | Press release
Christian brings more than 20 years of global experience in investment banking, private equity, and operational leadership, with a proven track record of driving transformational growth across industries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250512473756/en/ Christian Schütte Christian began his career at J.P. Morgan in New York and London, where he worked in the M&A and Corporate Finance teams. He later joined Fortress Investment Group and was instrumental in launching its German operations. During his tenure, he helped raise over €1.5 billion in equity and managed a wide array of investments, including non-performing and performing loans, private and public companies. He went on to join EQT Group, where he focused on mid-market growth and succession investments. Notably, he led the consolidation of nine digital marketing agencies into a €100 million market leader, building one of the most comprehensive digital ma
Introducing Joblio – The Future of Ethical Recruitment12.5.2025 19:30:00 EEST | Press release
Joblio, a global ethical recruitment platform, officially launches today to tackle the broken labor migration system—long plagued by exploitative intermediaries, high recruitment fees, and human rights abuses. With its tech-driven model, Joblio connects vetted workers with employers directly, eliminating unethical middlemen and ensuring cost-free hiring for migrant workers. Employers fund access to talent, but workers never pay—a key step in ending exploitation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250512628048/en/ A Mission Rooted in Personal Experience Joblio is led by Jon Purizhansky, a refugee-turned-entrepreneur who experienced migration challenges firsthand. Forced to flee his home country as a young man, Jon faced the uncertainty and vulnerability that millions of migrant workers still encounter today. Now a globally recognized expert in global labor migration law and international workforce mobility, Jon ha
DEWA Announces Record Quarterly Revenue of AED 5.96 Billion and Quarterly Cash from Operations of AED 3.85 Billion12.5.2025 18:06:00 EEST | Press release
Dubai Electricity and Water Authority PJSC (ISIN: AED001801011) (Symbol: DEWA), the Emirate of Dubai’s exclusive electricity and water services provider, listed on the Dubai Financial Market (DFM), reported its first quarter 2025 consolidated financial results, recording quarterly revenue of AED 5.96 billion, EBITDA of AED 2.43 billion, operating profit of AED 838 million and net profit of AED 496 million. The company also generated a record net cash from operations of AED 3.85 billion resulting in closing cash and cash equivalents of AED 8.17 billion, which is AED 2.07 billion higher than the balance as at year-end 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250512715455/en/ Dubai Electricity and Water Authority announces record quarterly revenue of AED 5.96 billion and quarterly Cash from Operations of AED 3.85 billion (English Graphic: AETOSWire) “We are progressing in our journey to Net Zero by 2050 and will con
Alisher Usmanov Wins Legal Case Against Luxembourg’s Largest Media Group, Says Law Firm Rechtsanwälte Steinhöfel12.5.2025 15:43:00 EEST | Press release
A German court has banned Mediahuis Luxembourg S.A., the most important media holding in Luxembourg, from referring to Alisher Usmanov as the owner of the yacht Dilbar. Mediahuis Luxembourg is the leading publishing company in Luxembourg, with such assets as newspapers and online platforms, including Luxemburger Wort, Luxembourg Times and others. On May 5, 2025, the Regional Court of Hamburg ruled that the following statement published by Luxembourg Times was false and prohibited its further publication: “The luxury yacht Dilbar was seized in Hamburg’s harbour in 2022 following Russia’s invasion under EU sanctions. The yacht is owned through a company and trust by Uzbek-Russian billionaire Alisher Usmanov.” The court found the statement to be in violation of Mr. Usmanov’s rights and prohibited its distribution. In the event of non-compliance with the prohibition, Mediahuis may be fined up to €250,000 for each individual offense. Moreover, if such a fine is not enforceable, it may be re
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom